Avastin Approved For Second-Line CRC
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech's Avastin gained approval June 20 for use in second-line treatment of metastatic colorectal cancer as an adjunct to chemotherapy, FDA said
You may also be interested in...
Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue
Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.
Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue
Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.
Genentech Aims To Extend Avastin Duration Of Use
Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.